Celcuity, Inc. (NASDAQ:CELC) Given Average Recommendation of “Moderate Buy” by Analysts

Celcuity, Inc. (NASDAQ:CELC) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eleven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $155.1818.

CELC has been the topic of several recent research reports. HC Wainwright raised their price objective on Celcuity from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Craig Hallum reissued a “buy” rating and issued a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Leerink Partners set a $155.00 target price on shares of Celcuity in a research note on Tuesday, June 2nd. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd.

Insider Buying and Selling at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Celcuity

Several large investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL purchased a new position in shares of Celcuity during the third quarter valued at about $1,351,000. Jennison Associates LLC purchased a new stake in shares of Celcuity in the fourth quarter worth about $22,911,000. Geode Capital Management LLC boosted its stake in Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after buying an additional 64,213 shares during the last quarter. Hsbc Holdings PLC bought a new position in Celcuity during the fourth quarter valued at approximately $1,058,000. Finally, TD Asset Management Inc grew its holdings in Celcuity by 34.0% during the 4th quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock valued at $9,727,000 after buying an additional 24,730 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Trading Down 2.0%

Shares of CELC stock opened at $88.34 on Friday. Celcuity has a 1 year low of $13.59 and a 1 year high of $151.02. The firm has a fifty day moving average price of $105.14 and a 200-day moving average price of $110.57. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The company has a market cap of $4.31 billion, a price-to-earnings ratio of -22.65 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities analysts predict that Celcuity will post -3.76 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.